Vancomycin-resistant enterococci historical perspective

Vancomycin-resistant enterococci Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Vancomycin-Resistant Enterococci from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Vancomycin-resistant enterococci historical perspective On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Vancomycin-resistant enterococci historical perspective All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA onVancomycin-resistant enterococci historical perspective
CDC on Vancomycin-resistant enterococci historical perspective
enterococci historical perspective in the news
on Vancomycin-resistant enterococci historical perspective
Directions to Hospitals Treating Vancomycin-resistant enterococci
Risk calculators and risk factors for Vancomycin-resistant enterococci historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.

Overview

Vancomycin-resistant enterococci (VRE), first reported in Europe in 1988, are emerging as a global threat to public health. The incidence of VRE infection and colonization among hospitalized patients has increased rapidly in the last 7 years. From 1989, the year VRE was first identified in the United States, through 1993, the proportion of enterococcal isolates resistant to vancomycin reported to the National Nosocomial Infections Surveillance System increased 20-fold.